

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

A retrospective study and survival analysis on bitches with mammary tumours spayed at the same time of mastectomy

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1799198> since 2021-09-02T10:32:28Z

Published version:

DOI:10.1111/vco.12759

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

A retrospective study and survival analysis on bitches with mammary tumors
spayed at the same time of mastectomy

Spaying bitches with mammary tumors

ABSTRACT

The aim of the present study was to retrospectively assess whether spaying at the same time of mastectomy increased disease-free survival (DFS) in bitches with mammary tumors and to investigate the utility of clinical data when designing a surgical plan that includes gonadectomy. Data from 225 bitches were retrieved. Only 116 were surgically treated. Among these, 52 bitches underwent mastectomy and ovariectomy and 46 bitches underwent mastectomy alone. Survival analysis by Kaplan-Meier and in-between groups comparisons using Student's T, Chi-square, and one-way ANOVA tests were performed. Eighteen bitches were already spayed. DFS was longer for bitches that underwent ovariectomy and mastectomy compared to those that were left intact ($P=0.00064$) or were already spayed ($P=0.0098$). Spaying status affected the tumor size (spayed: $2.75 \text{ cm} \pm 2.72$; intact: $1.76 \text{ cm} \pm 2.04$; $P=0.039$), but not malignancy ($P>0.05$). Differences in age were detected between animals with benign and malignant tumors (9.1 ± 2.8 and 10 ± 2.3 ; $P=0.004$), with multiple and single tumors (10.18 ± 2.6 and 9.3 ± 2.8 ; $P=0.007$), and between purebred and mixed breed bitches ($10.46 \text{ years} \pm 1.78$ and $9.27 \text{ years} \pm 2.68$; $P=0.005$). Malignant tumors were larger than benign ones ($2.17 \text{ years} \pm 2.31$ and $1.34 \text{ years} \pm 1.82$; $P=0.005$) and size increased according to the degree of malignancy. DFS was shorter for animals presenting tumors $>2 \text{ cm}$ in size ($P<0.006$) and with tumors in the first pair of thoracic mammary glands ($P=0.00009$). Gonadectomy should be suggested to owners of intact bitches carrying mammary tumors and age, size of the tumor, and location should be carefully considered when performing surgery.

Key words: Dog | mammary tumor | mastectomy | ovariectomy | [gonadectomy](#)

1. INTRODUCTION

Canine mammary tumors (CMTs) are the most common reproductive neoplastic disease in dogs and, generally, the most reported tumor in intact bitches¹. Surgery is the standard treatment, with good prognosis in animals with benign-to-low grade non metastatic tumors.

The role of ovarian steroids on carcinogenesis of the mammary gland has been the object of several studies in bitches. Sexual steroids act both under physiological and pathological conditions due to the presence of hormone receptors in mammary tissue²⁻⁴, and they may have an autocrine/paracrine

role in the growth of mammary tumors and in the maintenance of the disease⁵. Ductal growth is promoted by estrogens, whereas progesterone causes development and hyperplasia of lobulo-alveolar tissue⁶. Progesterone might be involved in the upregulation of growth hormone (GH) production within the mammary tissue, leading to proliferation of mammary stem cells that could have a primary role in carcinogenesis^{1, 7}. Hormonal stimulation of mammary tissue occurs at every estrous cycle, so that the reduction of risk of mammary cancer development has been calculated in relation to age (i.e., number of estrous cycles) at gonadal removal⁸⁻¹⁰. A systematic review of the literature on the effect of spaying on the risk of benign and malignant mammary tumors in the canine species, concluded that scientific evidence is too weak to serve as a basis for firm recommendation of spaying as a preventive measure¹¹. Nevertheless, epidemiological studies suggest that in countries where dogs are routinely spayed at an early age, the incidence of mammary neoplasms is lower (e.g., United States) when compared to countries where spaying is not routinely performed (e.g., Norway)^{12, 13}. On the other hand, associations between gonadectomy and other pathological conditions, such as urinary incontinence, cranial cruciate ligament rupture, hip dysplasia, osteosarcoma, and hemangiosarcoma have been recognized¹⁴. Hormonal deprivation following gonadal removal has also an impact on future health and longevity¹⁵. Therefore, surgical spaying of young healthy bitches should be performed based on a patient-specific approach, considering breed, age, surgical risk, and behavioral characteristics of the animal¹⁶.

Gonadectomy has also been suggested as an adjuvant treatment to mastectomy: bitches with benign mammary tumors and hyperplastic lesions that underwent both mastectomy and gonadal removal at the same time, were seen to have a 50% decrease in recurrence of disease¹⁷, whereas bitches with mammary carcinomas variably responded to neutering at the time of mastectomy⁶.

As literature data are not univocal and seem to suggest that gonadal removal in association with mastectomy can be beneficial mainly when hormone receptors are expressed by tumors, it would be very useful to re-evaluate this observation that is crucial for a clinician when suggesting the best treatment option for a patient.

Some history data, such as the reproductive condition, and some clinically assessable factors, such as age, tumor size and tumor number, have been described for risk of CMTs development and for their value in predicting malignancy. CMTs are typically diagnosed in older animals and the median age of occurrence ranges from 8 to 10 years¹⁸⁻²⁰. A correlation exists between tumor size and malignancy, with larger masses having higher risk of malignancy^{18, 21}. On the contrary, the presence of multiple tumors does not necessarily indicate a high degree of malignancy or a bad prognosis, because each neoplasm can belong to a different subtype^{21, 22}.

68 This study is a retrospective investigation aiming to assess whether spaying at the time of
69 mastectomy should be suggested to owners based on parameters collected in the context of the
70 clinical examination and on the analysis of disease-free survival.

71 2. MATERIALS AND METHODS

72 2.1 Data collection

73 The database of the *** was searched for records of bitches that had been presented because of
74 CMTs and that underwent mastectomy between January 2011 and January 2020. Each dog was
75 counted only once, irrespective of the number of visits, and records were evaluated retrospectively.
76 Only bitches with no previous history of mammary tumor were included. Data from animals that
77 did not undergo surgery were included only in the descriptive analysis. Proper informed consent
78 had been signed by the owners prior to surgery, allowing for surgical treatment and data collection
79 for research purposes.

80 Age, breed and spaying status of the patients, previous hormonal treatments, [previous pregnancies](#),
81 [pseudo-pregnancies](#), [previous reproductive conditions](#), clinical tumor features (number, location,
82 and size), and evaluation of regional lymph nodes were retrieved from the records.

83 The database contained also the standard pre-surgical diagnostics, such as blood exams, thoracic
84 radiographies, cardiological assessment and, in some cases, abdominal ultrasounds and cytologic
85 exams. All these preliminary exams had led to the decision of performing surgery.

86 Surgery type, either mastectomy alone or mastectomy and gonadectomy (ovariectomy or
87 ovari hysterectomy) had been recorded, together with the surgical approach for mastectomy and the
88 histological diagnosis. Histological classification and grading were based on criteria defined by
89 Zappulli (2019) and Peña (2019).

90 Follow-up data were obtained by the clinical records or by contacting the owners for a check-up
91 clinical examination at >365 days from surgery.

92 2.2 Analysis of data

93 Descriptive statistics was carried out considering data extracted from all retrieved clinical records
94 and data are presented as mean and standard deviation (SD) for continuous parameters or as
95 frequency for categories. Normality for continuous parameters was assessed by Shapiro-Wilk test.

96 Survival analysis was carried out using Kaplan-Meier method with log-rank tests and Bonferroni's
97 post hoc test to estimate differences in disease-free survival (DFS) among spayed bitches, intact

98 bitches that were subjected to mastectomy alone, and bitches that underwent mastectomy and
99 gonadectomy at the same time. Only bitches that underwent surgery and had the surgically excised
100 mammary tumor histologically evaluated were included. The same analysis was carried out to
101 estimate differences in disease-free survival (DFS) according to tumor size, malignancy, and tumor
102 location. Tumor size was considered as continuous; however, data were grouped in five categories
103 for the survival analysis (A < 1 cm, B = 1 to <2 cm, C = 2 to <3 cm, D = 3 to <5 cm, E > 5 cm)^{10, 21}.

104 Disease-free survival (DFS) was calculated from the time of surgery to the time of diagnosis of a
105 new mammary tumor. Bitches lost to follow-up and animals that died or that were euthanized for
106 causes unrelated to mammary tumors were censored at the time of death. Animals lost to follow-up
107 were censored at the time of their last contact with the clinician.

108 Student's T test for continuous normally distributed variables, Chi-square test, and one-way
109 ANOVA followed by Bonferroni's post hoc test for categories, were used to point out differences
110 based on age, breed, spaying status, tumor size, and malignancy of tumors in bitches that underwent
111 surgery.

112 Significance was considered for $P < 0.05$. Statistical analyses were performed with the software *R*
113 *version 3.2.2*.

114 3. RESULTS

115 Two-hundred and twenty-five bitches with a total number of 489 tumors were retrieved from the
116 database. Characteristics of the animals (age, purebred or mixed breed, and spaying status) and
117 characteristics of the tumors (size, number, location) are reported in *Table 1* and in *Table 2*. The
118 frequency of the different breeds is reported in Supplementary material (S1).

119 None of the included bitches had ever received any hormonal treatment during its lifetime or had
120 ever presented with any reproductive disease, according to information reported by owners.
121 Nevertheless, eight bitches had previous pregnancies (0.03%, five bitches had one previous
122 pregnancy, whereas three bitches had two previous pregnancies) and three bitches had previous
123 pseudo-pregnancies (0.01%). At clinical examination, 13 bitches (5.8%) presented altered regional
124 lymph nodes. Cytology was performed and they were included in the study only when the node was
125 not metastatic. Nine of these patients were deemed as node-positive after histology (69.2%),
126 whereas two of them presented just lymphadenitis (30.8%). The number of bitches that underwent
127 mastectomy and that were diagnosed with CMTs based on the histological examination was 116,
128 carrying a total number of 298 tumors. Frequencies of benign and malignant tumors are reported in

129 *Table 3.* Surgical margins were clear in all the bitches according to histological examination.
130 Histological types are reported in *Table 4*.

131 Tumor removal was carried out with different approaches, more frequently with a regional
132 mastectomy or with a combination of different techniques (i.e., regional mastectomy and simple
133 mastectomy), when tumors were present on both sides (*Table 5*).

134 Only 15.6% of the bitches that underwent surgery (n = 18) was already spayed and the
135 gonadectomy happened at least two years before mammary tumors occurrence. Fifty-two out of 98
136 intact bitches were spayed at the same time of mastectomy. Survival analysis showed a statistically
137 significant difference in DFS depending on spaying status (P = 0.0007). Specifically, bitches that
138 were subjected to spaying at the time of mastectomy showed longer DFS when compared with both
139 bitches that were already spayed (P = 0.0098) and bitches that remained intact (P = 0.00064).
140 However, median DFS for bitches that were subjected to spaying at the time of mastectomy was not
141 available because recurrence was < 50% in both intact bitches and bitches that were spayed at the
142 time of mastectomy (n = 9/64, 14% and n = 2/52, 3%, respectively). Recurrence in bitches that were
143 already spayed was 27.8% (n = 5/18) and their median DFS was 757 days (95% CI, 369-1026).

144 Statistically significant differences in mean age were detected between animals with benign and
145 malignant tumors, as shown in *Table 6*. Animals with multiple neoplasms were older than the ones
146 with single tumors ($10.18 \pm \text{SD } 2.6$ and $9.3 \pm \text{SD } 2.8$, respectively), with statistically significant
147 results (P = 0.004).

148
149 No differences between the incidence of benign and malignant tumors between purebred and mixed
150 breed animals were detected (P > 0.05), although purebred bitches had the tendency to develop
151 mammary tumors at a younger age (mean $10.46 \text{ years} \pm \text{SD } 1.78$) if compared to mixed breed ones
152 (mean $9.27 \text{ years} \pm \text{SD } 2.68$; P = 0.005).

153 Being already spayed did not affect the frequency of benign and malignant tumors (P > 0.05), nor
154 the degree of malignancy, I, II, or III (P > 0.05). However, intact bitches had smaller tumors when
155 compared to spayed ones (mean $1.76 \text{ cm}, \pm \text{SD } 2.04$ and $2.75 \text{ cm} \pm \text{SD } 2.72$, respectively;
156 P=0.003), although they showed a higher tendency to multiple tumors (P = 0.039).

157 Tumor size was statistically different between benign and malignant neoplasms (*Table 5*) and
158 differences in size were also detected based on the tumor grade, with grade III tumors being larger
159 than grades I and II (P = 0.05 and P = 0.003, respectively). Grade I malignant tumors had a mean

size of 2.1 cm (\pm SD 2.3), grade II malignant tumors had a mean size of 1.64 cm (\pm SD 1.1), and grade III malignant tumors had a mean size of 3.6 cm (\pm SD 2.2).

Survival analysis showed a statistically significant difference in DFS depending on the size of mammary tumors ($P = 0.003$), considering the five classes mentioned in subsection 2.2. Specifically, smaller tumors belonging to classes A and B had a longer DFS when compared to larger tumors belonging to class E ($P = 0.002$ and $P = 0.006$, respectively; A: median DFS 2102 days, 95% CI 1143-2385; B: median DFS 1148 days, 95% CI 1076-2267; D: median DFS 669 days, 95% CI 434-669; E: median DFS 359, 95% CI 72-811). Class C included a low number of data, that were insufficient to the purpose of Kaplan-Meier analysis.

Survival analysis showed also a statistically significant difference in DFS depending on location of mammary tumors ($P = 0.00009$). Animals presenting with neoplasms located in the cranial thoracic mammary glands (I pair), had a worse prognosis for mammary tumors recurrence (I: median DFS 434 days, 95% CI 188-434; II: median DFS 1143 days, 95% CI 659-1143; III: median DFS 1502 CI 811-2385; IV: median DFS 1259 days, 95% CI 1096-2385; V: median DFS 1148, 95% CI 759-2385). No differences in DFS were detected between bitches presenting with single and multiple tumors ($P > 0.05$).

4. DISCUSSION

The effect on time free of disease of OHE at the same time of mastectomy was evaluated in a mixed population of bitches affected by mammary tumors at different stages. The population included in the present study shared some common characteristics to those included in previous studies in terms of age, breed, spaying status, and mean size of benign and malignant tumors^{18-21, 25} and additional factors such as location and number of tumors were assessed. The typical presentation for the diagnosis of canine mammary tumor is middle-aged non-spayed purebred bitches, however younger and mixed breed animals can be affected.

Spaying status effect on canine mammary tumors has been widely investigated, with contradictory results¹¹. It is commonly known that spaying before the first estrus comes with a lower risk of mammary tumors development⁸, and this confirms the involvement of ovarian steroids in mammary tissue carcinogenesis. Accordingly, our data showed that the number of spayed bitches presenting with CMTs was consistently lower than the number of intact ones. However, this might be also the consequence of a smaller general population of spayed animals in Italy, compared to the one of intact bitches. There is no data in the literature about the population of ovariectomized bitches, although spaying is a rather diffuse practice in Italy. Nevertheless, early spaying is becoming less

192 popular when balancing benefits and possible adverse effects.

193 Some owners decided upon mastectomy alone, notwithstanding the fact that gonadectomy was
194 always recommended to owners of intact bitches presenting with CMTs, when overall clinical
195 conditions made it advisable. The recommendation was based on the higher risk of uterine and
196 ovarian disease in middle-aged and old bitches²⁶ and on the higher risk of new malignant CMTs in
197 bitches with a previous history of malignant CMT²⁷. The reasons underneath this increased risk of
198 CMTs might be well explained by the hormonal effect to which the whole mammary tissue is
199 exposed to¹. Furthermore, the positive effect of gonadectomy at the time of mastectomy as an
200 adjuvant therapy has been investigated, with encouraging results especially on
201 hyperplastic/dysplastic and benign mammary diseases¹⁷ and bitches with grade II carcinomas
202 presenting estrogen receptors or with increased peri-surgical serum concentrations of 17 β -estradiol⁶.
203 However, to classify a tumor as hormonally dependent, receptors for sexual steroids need to be
204 detected on neoplastic tissue. Some authors relate a decrease in receptors for ovarian steroids with a
205 worse prognosis^{28, 29}. Therefore, including the search of receptors for both estrogens and
206 progesterone in post-surgical investigations in intact bitches, could represent a very useful tool to
207 improve prognostic precision and treatment protocols¹.

208 The observation on hormone receptors in the removed tumors could not be included because it was
209 not available in the database, and this represents an important limitation. However, when the
210 clinician suggests a treatment option, he cannot rely on this information and focuses on general
211 findings only. Results on DFS and rate of recurrence of CMTs in bitches that were spayed at the
212 time of mastectomy were encouraging. Patients that remained intact had higher recurrence of
213 CMTs. The fact that recurrence was even higher in already spayed bitches should be furtherly
214 investigated in order to point out factors influencing mammary tissue carcinogenesis in the absence
215 of hormonal stimulation. In addition, our results agree with those of Burrai *et al.* (2020), showing
216 that spaying status had no significant influence on whether tumors were benign or malignant. The
217 limited number of spayed bitches included does not allow us to consider malignancy responsible for
218 higher recurrence rates in spayed bitches.

219 The decisional process of the clinician should start with a complete evaluation of the patient, in
220 order to assess its suitability for mastectomy and to decide the appropriate surgical technique and
221 whether to include gonadectomy in its surgical plan. Patients presenting with mammary tumors
222 should be carefully checked for evidence of metastatic disease³⁰, starting with the evaluation of
223 regional lymph nodes. These organs are difficult to assess when normal, and the easily palpable
224 ones should be checked, possibly indicating regional metastasis^{1, 31}, to be confirmed through
225 cytological examination. There is evidence that disease-free survival is shorter and survival rate is

226 lower in node positive patients³². Other clinical parameters are related to malignancy and prognosis.
227 Age is a risk factor for neoplastic disease in general³³, and the median age of occurrence of CMTs
228 ranges from 8 to 10 years¹⁸⁻²⁰, in accordance with our results, that also agree on the fact that median
229 age of bitches with benign tumors is lower than age of animals with malignant ones²¹.
230 Incidence of CMTs in purebred animals was higher than in mixed breed bitches and frequencies are
231 coherent with information reported in studies that indicate a higher risk of CMTs in breeds such as
232 Poodles, English Springer Spaniels, Brittany Spaniels, German Shepherds, Maltese terriers,
233 Yorkshire Terriers, Dachshunds, Doberman Pinschers, Leonbergers, and Boxers^{1, 34-35}. However,
234 few studies investigate the genetic predisposition of specific breeds towards mammary subtypes^{36, 37}
235 and further studies should be conducted.

236 Majority of patients carried multiple nodules and had malignant neoplasms, although a lower degree
237 of malignancy was more common than higher ones. In general, older animals have the tendency to
238 carry multiple nodules and are expected to be diagnosed with malignant neoplasms. The presence of
239 multiple nodules does not necessarily indicate a high degree of malignancy or a bad prognosis,
240 because each neoplasm can belong to a different subtype^{21, 22}.

241 Some studies indicate that tumor location is not associated with tumor type³⁸ nor with survival
242 time³⁸, whereas a more recent paper³⁹ indicates tumor location as predictive of malignancy, with a
243 significantly higher proportion of malignant tumors developing in the inguinal mammary glands.
244 We found that incidence of nodules progressively increased from cranial to caudal mammary
245 glands, probably because caudal abdominal and inguinal mammary glands physiologically have
246 more abundant parenchyma⁴⁰. In contrast with Ariyaratna *et al.* (2018), no difference in
247 malignancy occurred according to tumor location, although a lower DFS was pointed out for bitches
248 presented with nodules located in the first thoracic pair of mammary glands. This should be kept in
249 mind by the surgeon, because more invasive surgery could be considered in these cases, although
250 prospective studies correlating surgical techniques with tumor location represent an area for further
251 research.

252 In accordance with other studies^{18-19, 21}, size of the tumor is another important clinical parameter
253 with prognostic value, with malignant tumors being generally larger than benign ones. Our results
254 show that among malignant tumors, larger size corresponds to higher malignancy grade and lower
255 DFS.

256 We conclude that spaying at the time of mastectomy should always be considered in intact bitches
257 with mammary tumors, possibly followed by the additional assessment of hormone receptors
258 presence on the removed tumors. Intact bitches around 9 years old, have higher probability to

259 develop mammary tumors and older age of bitches and tumors size larger than 2 cm are more
260 commonly related to malignant neoplasms. Location should be carefully considered when designing
261 the surgical plan, because bitches with nodules located in the cranial thoracic mammary glands have
262 a shorter time free of mammary tumors. This will help the clinician to make a more precise
263 prognosis to the patient.

264 5. REFERENCES

- 265 [1] Sleeckx N, de Rooster H, Veldhuis Kroeze E, Van Ginneken C, Van Brantegem L. Canine
266 Mammary Tumours, an Overview. *Reprod Domest Anim* 2011; 46:1112-1131.
267
- 268 [2] MacEwen EG, Patnaik AK, Harvey HJ, Panko WB. Estrogen receptors in canine mammary
269 tumors. *Cancer Res* 1982; 42(6):2255-2259.
270
- 271 [3] Rutteman GR, Misdorp W, Blankenstein MA, van den Brom WE. Oestrogen (ER) and progestin
272 receptors (PR) in mammary tissue of the female dog: different receptor profile in non-malignant and
273 malignant states. *Br J Cancer* 1988; 58(5):594-599.
274
- 275 [4] Mainenti M, Rasotto R, Carnier P, Zappulli V. Oestrogen and progesterone receptor expression
276 in subtypes of canine mammary tumours in intact and ovariectomised dogs. *Vet J* 2014; 202(1):62-
277 68.
278
- 279 [5] Queiroga FL, Pérez-Alenza MD, Silvan G, Peña L, Lopes C, Illera JC. Role of steroid hormones
280 and prolactin in canine mammary cancer. *J Steroid Biochem Mol Biol* 2005; 94(1-3):181-187.
281
- 282 [6] Kristiansen VM, Peña L, Díez Córdova L, et al. Effect of Ovariohysterectomy at the Time of
283 Tumor Removal in Dogs with Mammary Carcinomas: A Randomized Controlled Trial. *J Vet Intern*
284 *Med* 2016; 30(1):230-241.
285
- 286 [7] Queiroga FL, Pérez-Alenza MD, Silvan G, Peña L, Lopes CS, Illera JC. Crosstalk between
287 GH/IGF-I axis and steroid hormones (progesterone, 17beta-estradiol) in canine mammary tumours.
288 *J Steroid Biochem Mol Biol* 2008; 110:76-82.
289
- 290 [8] Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development
291 and postsurgical survival. *J Natl Cancer Inst* 1969; 43(6):1249-1261.
292
- 293 [9] Misdorp, W. Canine mammary tumours: protective effect of late ovariectomy and stimulating
294 effect of progestins. *Vet Q* 1988; 10:26-33.
295
- 296 [10] Sorenmo KU, Worley DR, Zappulli V. Tumors of the Mammary Gland. In: Withrow SJ, Vail
297 DV, Thamm DH, Liptak JM eds. *Withrow & MacEwen's Small Animal Clinical Oncology*. 6th ed.
298 St. Louis, MO: Elsevier; 2019:604–615.
299
- 300 [11] Beauvais W, Cardwell JM, Brodbelt DC. The effect of neutering on the risk of mammary
301 tumours in dogs – a systematic review. *J Small Anim Pract* 2012; 53:314-322.
302
- 303 [12] Moe L. Population-based incidence of mammary tumours in some dog breeds. *J Reprod Fertil*
304 2001; 57:439-443.

305
306
307
308
309
310
311
312
313
314
315

316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331

332
333
334

335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350

[13] Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. *Prev Vet Med* 2005; 69(1-2):109-127.

[14] Howe LM. Current perspectives on the optimal age to spay/castrate dogs and cats. *Vet Med (Auckl)* 2015; 6:171-180.

[15] Waters DJ, Kengeri SS, Maras AH, Suckow CL, Chiang EC. Life course analysis of the impact of mammary cancer and pyometra on age-anchored life expectancy in female Rottweilers: implications for envisioning ovary conservation as a strategy to promote healthy longevity in pet dogs. *Vet J* 2017; 224:25–37.

[16] Hart BL, Hart LA, Thigpen AP, Willits NH. Assisting decision-making on age of neutering for 35 breeds of dogs: associated joint disorders, cancers, and urinary incontinence. *Front Vet Sci* 2020; 7:388.

[17] Kristiansen VM, Nødtvedt A, Breen AM, et al. Effect of ovariohysterectomy at the time of tumor removal in dogs with benign mammary tumors and hyperplastic lesions: a randomized controlled clinical trial. *J Vet Intern Med* 2013; 27(4):935-942.

[18] Gedon J, Wehrend A, Failing K, Kessler M. Canine mammary tumours: Size matters-a progression from low to highly malignant subtypes. *Vet Comp Oncol* 2020; 1-7.

[19] Burrai GP, Gabrieli A, Moccia V, et al. A Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study. *Animals (Basel)* 2020;10(9):1687.

[20] Canadas A, França M, Pereira C, et al. Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study. *Vet Pathol* 2019; 56(2):208-219.

[21] Sorenmo KU, Kristiansen VM, Cofone MA, et al. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. *Vet. Comp. Oncol* 2009; 7:162–172.

[22] Sorenmo K. Canine mammary gland tumors. *Vet Clin North Am Small Anim Pract* 2003; 33(3):573-596.

[23] Zapulli et al. Surgical Pathology of Tumors of Domestic Animals. In Kiupel ed: Vol 2: Mammary Tumors, 2019.

[24] Peña L, Gama A, Goldschmidt MH, et al. Canine mammary tumors: a review and consensus of standard guidelines on epithelial and myoepithelial phenotype markers, HER2, and hormone receptor assessment using immunohistochemistry. *Vet Pathol* 2014; 51(1):127-145.

[25] Gunnes G, Borge KS, Lingaas F. A statistical assessment of the biological relationship between simultaneous canine mammary tumours. *Vet Comp Oncol* 2017; 15(2):355-365.

[26] Egenvall A, Hagman R, Bonnett BN, Hedhammar A, Olson P, Lagerstedt AS. Breed risk of pyometra in insured dogs in Sweden. *J Vet Intern Med* 2001; 15(6):530-8.

351 [27] Stratmann N, Failing K, Richter A, Wehrend A. Mammary tumor recurrence in bitches after
352 regional mastectomy. *Vet Surg* 2008; 37(1):82-86.
353

354 [28] Chang CC, Tsai MH, Liao JW, Chan JP, Wong ML, Chang SC. Evaluation of hormone
355 receptor expression for use in predicting survival of female dogs with malignant mammary gland
356 tumors. *J Am Vet Med Assoc* 2009; 235(4):391-396.

357 [29] Gama A, Alves A, Schmitt FC. Clinicopathologic features of mammary invasive
358 micropapillary carcinoma (IMC) in dogs. *Vet Pathol* 2008; 45(4):600-601

359 [30] Fesseha H. Mammary Tumours in Dogs and its Treatment Option- A Review. *Biomed J Sci &*
360 *Tech Res* 2020; 30(4):23552-23561.

361 [31] de Araújo MR, Campos LC, Ferreira E, Cassali GD. Quantitation of the Regional Lymph Node
362 Metastatic Burden and Prognosis in Malignant Mammary Tumors of Dogs. *J Vet Intern Med* 2015;
363 29(5):1360-1367.
364

365 [32] Tuohy JL, Milgram J, Worley DR, Dernell WS. A review of sentinel lymph node evaluation
366 and the need for its incorporation into veterinary oncology. *Vet Comp Oncol* 2009; 7:81-91.
367

368 [33] Biller B, Berg J, Garrett L, et al. 2016 AAHA Oncology Guidelines for Dogs and Cats*. *J Am*
369 *Anim Hosp Assoc* 2016; 52(4):181-204.
370

371 [34] Dobson JM. Breed-predispositions to cancer in pedigree dogs. *ISRN Vet Sci* 2013;
372 2013:941275.
373

374 [35] Jitpean S, Hagman R, Ström Holst B, Höglund OV, Pettersson A, Egenvall A. Breed variations
375 in the incidence of pyometra and mammary tumours in Swedish dogs. *Reprod Domest Anim* 2012;
376 47 Suppl 6:347-350.
377

378 [36] Kim HW, Lim HY, Shin JI, Seung BJ, Ju JH, Sur JH. Breed- and age-related differences in
379 canine mammary tumors. *Can J Vet Res* 2016; 80(2):146-155
380

381 [37] Im KS, Kim IH, Kim NH, Lim HY, Kim JH, Sur JH. Breed-related differences in altered
382 BRCA1 expression, phenotype and subtype in malignant canine mammary tumors. *Vet J* 2013;
383 195(3):366-372.
384

385 [38] Hellmen E, Lindgren A, Linell F, Matsson P, Nilsson A. Comparison of Histology and Clinical
386 Variables to DNA Ploidy in Canine Mammary Tumors. *Vet Pathol* 1988; 25(3):219-226.
387

388 [39] Ariyaratna H, de Silva N, Aberdein D, et al. Clinicopathological Diversity of Canine
389 Mammary Gland Tumors in Sri Lanka: A One-Year Survey on Cases Presented to Two Veterinary
390 Practices. *Vet Sci* 2018; 5(2):46.
391

392 [40] Baba AI, Cătoi C. Mammary Gland Tumors. In: *Comparative Oncology*. Bucharest (RO), The
393 Publishing House of the Romanian Academy; 2007. Available from:
394 <https://www.ncbi.nlm.nih.gov/books/NBK9542/>
395
396

Table 1. Frequencies of some parameters of bitches with CMTs (n = 225) and tumors (n = 489).

	Spaying status			Breed		Number of tumors†		Location of tumors				
	Intact	Spayed	N/A	Purebred	Mixed breed	Single tumor	Multiple tumors	I	II	III	IV	V
n	141	31	53	145	80	78	147	22	56	104	143	164
Percentage (%)	62.7	13.8	23.5	64.4	35.5	34.7	65.3	4.4	11.5	21.3	29.2	33.6

†Bitches with single or multiple neoplasms.

400
401

Table 2. Mean and standard deviation (SD) of age of the bitches included in the study (n = 225) and size of the tumors.

	Mean	±SD
Age (years)	9.8	2.8
Size of tumors (cm)	2.1	4.8

402
403

Table 3. Frequency of benign and malignant tumors with degree of malignancy

	Benign tumors	Malignant tumors		
		I degree	II degree	III degree
n	88	134	43	20.4
Percentage (%)	29.5	63.9	20.4	15.7

Table 4. Histological diagnosis (number: n and percentage: %)

	n	Percentage (%)
Simple benign tumors		
Adenoma, simple	32	10.7
Ductal-associated benign tumors		
Intraductal papillary adenoma	26	8.9
Nonsimple benign tumors		
Complex adenoma	10	3.4

Benign mixed tumor	12	4
Fibroadenoma	8	2.7
Simple carcinoma		
Carcinoma, simple	27	9.1
Tubopapillary carcinoma	51	17.1
Solid carcinoma	2	0.6
Nonsimple carcinoma		
Carcinoma in a benign mixed tumor	21	7
Complex carcinoma	99	33.2
Others		
Adenosquamous carcinoma	4	1.3
Carcinosarcoma	3	1
Myoepithelioma	2	0.6
Osteosarcoma	1	0.4

Table 5. Frequencies of surgical techniques for mastectomy in 116 bitches.

	<i>n</i>	<i>Percentage (%)</i>
Lumpectomy	14	12
Simple mastectomy	15	13
Regional mastectomy	39	33.5
Unilateral mastectomy	18	15.5
Combination of techniques	30	26%

Table 6. Differences (mean and standard deviation: SD) in age and tumor size in bitches with benign or malignant tumors.

	Age (years)			Size (cm)		
	Mean	SD	P-value	Mean	SD	P-value
Benign tumors	9.1	2.8	0.007*	1.34	1.82	0.004*
Malignant tumors	10	2.3		2.17	2.31	

*Significance for $P < 0.05$